CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences

HUMAN GENE THERAPY · Available online 10 Jul 2026 · In press · DOI 10.1177/10430342261467645

Authors (2)

Duc-Hiep Bach, Thanh Liem Nguyen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Bach, D., Nguyen, T. (2026). CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences. HUMAN GENE THERAPY. https://doi.org/10.1177/10430342261467645

Related articles

• Retroviral Transduction of Human CD4 + T Cells with Membrane-Attached IL-10 Generates Type 1-Like Regulatory T Cells · HUMAN GENE THERAPY · 2026 · Same journal
• Optimization of Alpha-1 Antitrypsin Expression from Adeno-Associated Virus Vectors · HUMAN GENE THERAPY · 2026 · Same journal
• Prenatal Intraportal Delivery of Polymeric Nanoparticles to Fetal Rhesus Monkeys ( Macaca mulatta ) · HUMAN GENE THERAPY · 2026 · Same journal
• High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia · HUMAN GENE THERAPY · 2026 · Same journal
• Quantification of Lentiviral Vectors with Nucleic Acid Dyes · HUMAN GENE THERAPY · 2026 · Same journal
• A Review of the Challenge of Pre-Existing Humoral Immunity in Adeno-Associated Virus Gene Therapy and Potential Solutions · HUMAN GENE THERAPY · 2026 · Same journal
• Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases · HUMAN GENE THERAPY · 2026 · Same journal
• Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome Editing · HUMAN GENE THERAPY · 2026 · Same journal
• Helper-Dependent Adenoviral Vectors: Recent Advances and Emerging Applications · HUMAN GENE THERAPY · 2026 · Same journal
• AviNP-Seq: A Blindspot-Free Single-Molecule Framework for Unmasking AAV Genome Heterogeneity and Determining Packaging Limits · HUMAN GENE THERAPY · 2026 · Same journal